Background: We previously showed, in patients with diabetes, that >50% of monitoring tests for glycated haemoglobin (HbA 1c ) are outside recommended intervals and that this is linked to diabetes control. Here, we examined the effect of tests/year on achievement of commonly utilised HbA 1c targets and on HbA 1c changes over time. Methods: Data on 20,690 adults with diabetes with a baseline HbA 1c of >53 mmol/mol (7%) were extracted from Clinical Biochemistry Laboratory records at three UK hospitals. We examined the effect of HbA 1c tests/year on (i) the probability of achieving targets of ≤53 mmol/mol (7%) and ≤48 mmol/mol (6.5%) in a year using multistate modelling and (ii) the changes in mean HbA 1c using a linear mixed-effects model.
Introduction
Achieving and maintaining adequate glycaemic control, as measured by glycated haemoglobin (HbA 1c ), is the focus of management strategies for patients with diabetes mellitus (DM). Guidance from many professional bodies worldwide recommends regular HbA 1c monitoring to optimise the chances of attaining treatment goals for these patients. American Diabetes Association guidelines recommend testing "at least two times a year in patients who are meeting treatment goals (and who have stable glycaemic control)" and "quarterly in patients whose therapy has changed or who are not meeting glycaemic goals" [1] , whereas the UK National Institute for Health and Care Excellence guidance recommends measuring HbA 1c at "3-6-monthly intervals…, until the HbA 1c is stable on unchanging therapy" and "6-monthly intervals once the HbA 1c level and blood glucose lowering therapy are stable" [2, 3] .
Although guidance on monitoring frequency is clear, studies have shown that many patients do not have tests at the recommended frequency [4] [5] [6] [7] [8] [9] [10] [11] . For example, an Australian study [10] showed that, of patients with HbA 1c >53 mmol/mol (>7%), only 22.9% received a follow-up test within the recommended 3-monthly interval over the 24-month study period, whereas we showed that >50% of all tests are requested outside recommended monitoring intervals (21% too soon; 30% too late) [7] . We have observed this phenomenon in other cases where scheduled testing is required [12] . This raises questions as to the implications of inadequate, excessive or inappropriate monitoring, on both clinical and economic endpoints [11] . In an attempt to provide some validation of recommended intervals, Parcero et al. [13] , in a study of 193 patients with diabetes in general practice, found that median HbA 1c values in patients who were tested at recommended intervals were significantly lower than those in patients with intervals that did not adhere to guidelines. Furthermore, we have previously shown that HbA 1c monitoring interval is associated with changes in diabetes control, as measured by difference in HbA 1c levels between consecutive tests [11] , whereas Phan et al. [14] showed that excessive or infrequent testing was associated with a higher proportion of patients with worsening glycaemic control. Fu et al. [15] also studied the relationship between patient-reported HbA 1c testing frequency and optimal glycaemic control defined as a target HbA 1c of <53 mmol/mol (<7%). They showed that, after adjusting for age, gender, education level and lifestyle factors, patients with two or more tests/year were more likely to have an HbA 1c below target than those with either one or no tests during that period.
With regard to patient management, the most important decision is how frequently to test in order to achieve the patient treatment goal. Although Fu et al. [15] sought to address this, their analysis was cross sectional and did not subclassify patients with two or more tests/year. Loh et al. [16] indicated that testing more frequently than every 4 weeks was not justified, whereas Phan et al. [14] indicated that, in young patients with type 1 diabetes, four tests/year was least likely to result in worsening control. Nevertheless, the wider question of optimum number of test/year to attain the target HbA 1c remains elusive.
In this study, we hypothesised that requesting HbA 1c tests at recommended frequency would result in a higher proportion achieving target and reduced overall HbA 1c levels within 1 year. We analysed 4 years of HbA 1c records from a cohort of patients with HbA 1c levels >53 mmol/mol (7%) at baseline from a data set of 39,138 patients with DM across three UK centres. We developed dynamic modelling based on multistate models to examine the effect of number of tests/year on the probability of achieving targets of 53 mmol/mol (7%) and 48 mmol/mol (6.5%), as suggested in most guidance [1] [2] [3] . Additionally, we examined the effect of frequency of testing on HbA 1c levels over the course of the 4 years using longitudinal modelling.
Materials and methods

Patients
This study involved patient level data collected as part of routine clinical practice from clinical laboratory databases. Data on all HbA 1c test requests from 39,138 patients >16 years old collected from 2007 to 2011 were extracted from the Clinical Biochemistry Laboratory Information Management Systems at the University Hospital of North Midlands NHS Trust (UHNM), Royal Wolverhampton NHS Trust (RWT) and Salford Royal NHS Foundation Trust (SRFT) [7, 11] . HbA 1c concentrations were obtained using either cation-exchange high-performance liquid chromatography (Tosoh G8; UHNM and RWT) or borate affinity high-performance liquid chromatography (Menarini Hb9210; SRFT) methodology, with a between batch coefficient of variation of <2%. In each laboratory, external quality assurance was provided by membership of the UK National External Quality Assurance Scheme. From this data set, we examined the cohort of patients who had a baseline HbA 1c test above 53 mmol/mol (7%) and at least one further HbA 1c requested on an annual anniversary (i.e. at intervals of 365 days ± 30 days) during the study period. These comprised 20,836 individuals, 53.2% of the original data set; 146 were excluded due to missing HbA 1c levels. This left a core data set of 20,690 participants (3483 from SRFT, 9502 from UHNM and 7705 from RWT), including information on dates of requested tests in the course of 4 years, HbA 1c levels, age, sex and centre.
Model development and study design
Rates of transition and probability of achieving HbA 1c target: The main objective was to examine the effect of frequency of testing on the probability of achieving a target A time-varying categorical variable "frequency of testing" was created to indicate the number of tests a patient had within his/her previous year's record (excluding the baseline test), with a value of "1" if the patient had just one additional test and values of "2", "3", "4" and ">4" if the patient had 2, 3, 4, or 5 or more additional tests, respectively.
The hazard functions of transition were modelled in terms of frequency of testing, sex, age and centre. In addition, the model was stratified by baseline HbA 1c category (53-64, 64-75, 75-86, 86-108 and >108 mmol/mol [7%-8%, 8%-9%, 9%-10%, 10%-12% and >12%]) to give an indication of the initial degree of suboptimal control.
The focus of the analysis was the rate of transition from "HbA 1c level > target" to "HbA 1c level ≤ target"; this provides a dynamic assessment of glycaemic control. Estimates of the hazard ratios are reported for each explanatory variable. For a categorical variable (e.g. frequency of testing), the hazard ratio represents the ratio of transition rates for each category compared with a reference category. For a continuous variable (e.g. age), the hazard ratio is the ratio of transition rates for two individuals with one unit difference. A hazard ratio value of one indicates no difference in rates. Finally, from this model, the probability of moving from the state "HbA 1c level > target" to the state "HbA 1c level ≤ target" during 1 year was calculated overall and by frequency of testing, holding the values of other explanatory variables fixed at their mean value.
Changes of HbA 1c levels over time: The second objective was to assess the effect of frequency of testing on changes in HbA 1c levels over time. A linear mixed-effects regression model with a random intercept was fitted to HbA 1c levels, after screening of the sampling distribution of the data to check that the distribution was symmetric. The linear regression model included frequency of testing, sex, age (centred on the baseline mean), centre, a categorical variable for time from baseline as explanatory variables and a random intercept. A quadratic term for age was also included to assess departures from the assumption of linearity between HbA 1c levels and age.
Statistical analysis
As described above, the effect of frequency of testing on the probability of achieving a target HbA 1c level (≤53 mmol/mol [≤7%] or ≤48 mmol/mol [≤6.5%]) for patients with suboptimal control at baseline was analysed using multistate model for each target. A linear mixed-effects regression model with a random intercept was used to assess effect of testing frequency on HbA 1c levels. All models were fitted by maximum likelihood estimation. p-Values for the linear random effects model were calculated using Wald tests. All analyses were performed using the statistical software R [18] with the packages "msm" [19] and "lme4" [20] .
Results
Descriptive statistics
The cohort of 20,690 patients (55.9% male) had a median age of 62 years (IQR = 51-71 years) and a median HbA 1c concentration of 65 mmol/mol (IQR = 57.4-79.2 mmol/mol; 8.1%, IQR = 7.4%-9.4%) at baseline. Of these, 11, 872 patients contributed data at baseline and 1 year, 5952 with an additional year, 2187 with 3 years and 572 with four consecutive years after baseline. The remaining 107 cases contributed data at baseline and other combinations of years (e.g. 22 cases contributed data at baseline, and years 1 and 3).
In the course of the 4 years, in only 20.4% (6137/30,054) of instances did the HbA 1c level change from >53 mmol/mol (>7%; above target) to ≤53 mmol/ mol (≤7%; below target) between two consecutive years. Changes from HbA 1c >48 mmol/mol (>6.5%) to HbA 1c ≤48 mmol/mol (≤6.5%) were observed in only 10.0% (3139/31,540) of occasions.
The box plots in Supplementary Figure S1 show the empirical distribution of HbA 1c levels by the frequency of testing. Although this does not account for the correlation among observations from the same individual or the effect of time, it is apparent that the overall HbA 1c levels were similar across the groups.
Rates of transition and probability of achieving HbA 1c target Table 1 shows the hazard ratio estimates of a transition from HbA 1c > target to HbA 1c ≤ target. There was no difference in rates of achieving either target between females and males. However, the hazard ratio for age was greater than 1, indicating that older patients are more likely to achieve target. There were also differences between centres, with cases from RWT more likely to achieve the 53 mmol/mol (7%) target, and those from both UHNM and RWT less likely to achieve the 48 mmol/mol (6.5%) target relative to SRFT. As expected, cases with a higher baseline HbA 1c were less likely to achieve the targets compared with those with an initial HbA 1c of 53-64 mmol/mol (7%-8%), although those with a baseline HbA 1c of >108 mmol/mol (>12%) were generally more likely to achieve target than those with values between 64 and 108 mmol/mol (8%-12%).
As most guidelines on frequency of monitoring for suboptimally controlled patients recommend four tests/year, this was chosen as comparator (reference category) in the assessment of effect of testing frequency on achievement of target. The proportion achieving either 53 mmol/mol (7%) or 48 mmol/mol (6.5%) targets were similar for those patients who were monitored twice or three times a year, to those the reference category (four tests/year). By contrast, compared with four tests/year, there was a 33% and 25% decrease in the rates of achieving the 53 mmol/mol (7%) target for monitoring frequencies of one and more than four times/year, respectively. Similarly, those who were monitored one time or more than four times had 39% and 20% reduction in the rates of achieving the 48-mmol/mol target, respectively. Table 2 shows the estimated probability of each possible transition, holding the explanatory variables fixed at their mean value. The overall probability of achieving the 53 mmol/mol (7%) target for patients who were suboptimally controlled the previous year was 0.20 (95% CI: 0.19, 0.21) and 0.10 (95% CI: 0.09, 0.10) for the 6.5%
(48 mmol/mol) threshold. Thus, only 20% of cases were predicted to achieve the 53 mmol/mol (7%) target. Furthermore, once this target was achieved, 52% of cases were predicted to remain within target in the subsequent year. Similarly, for the 48 mmol/mol (6.5%) target, only 10% were predicted to achieve target and 52% predicted to subsequently remain within this target. Figure 1 provides a graphical representation of the probability of achieving the HbA 1c target in 1 year overall and by frequency of testing. The probability of achieving For example, the probabilities of achieving targets of ≤53 mmol/mol (7%) and ≤48 mmol/mol (6.5%), with a starting point of >53 mmol/mol (>7%), are presented in bold. Similarly, the probabilities of remaining below a target of ≤53 mmol/mol (7%), once achieved, are presented in italics. the target is comparable when two or three tests are done compared with four for both thresholds. However, both one test/year and more than four tests/year had a lower probability of achieving either target. 
Changes of HbA 1c levels over time
Discussion
We demonstrated, using dynamic modelling, in a large cohort of suboptimally controlled patients with diabetes across three UK centres, that (i) 80% of patients fail to achieve a target of ≤53 mmol/mol (≤7%) within 1 year (90% fail to achieve a target of ≤48 mmol/mol [≤6.5%]), and (ii) overall, two or three HbA 1c tests/year are equivalent to four tests at achieving HbA 1c target values, but one test per year was inadequate; there was no added benefit in carrying out more than four HbA 1c tests/year.
Rates of transition and probability of achieving HbA 1c target Overall probability of achieving targets
The large number of patients with suboptimal control who do not reach recommended targets, despite regular monitoring, is of major concern. Our findings that only ~20% of patients with HbA 1c >53 mmol/mol (>7%) attain a target level of ≤53 mmol/mol (≤7%) 1 year later are similar to the 32% seen by Anichini et al. [21] in a small cross-sectional sample (n = 315) with a similar baseline [10] , only 18.5% of cases with a baseline HbA 1c of >53 mmol/mol (>7%) had a subsequent test result below 53 mmol/mol (7%) over the 2-year follow-up period. Hence, in spite of the resources put into diabetes management, many patients remain above target HbA 1c , with all the attendant adverse longterm health consequences for the individual [22] [23] [24] .
Effect of monitoring frequency
Our analysis then focussed on assessment of the effect of monitoring frequency on the rate of transitions from suboptimal to target glycaemic control. Our multistate model accommodated the adjustment to monitoring frequency that is likely to occur, for a given patient, following a high HbA 1c measurement, thus providing a dynamic assessment of glycaemic control. Our results clearly show that annual testing is inadequate, yielding a 33% reduced likelihood of achieving control compared with four tests/year.
Our data are consistent with the work of Fu et al. [15] in 1511 patients with type 2 diabetes attending outpatient clinics, where they identified that two or more tests/year resulted in a higher proportion of patients having a HbA 1c of <53 mmol/mol (<7%) (26.8%) compared with those who had one test/year (24.8%). However, our analysis extends this in indicating that more than three to four tests/year offer limited additional benefit in this regard, whereas more than four tests/year resulted in a reduced probability of achieving target. This is largely in keeping with recommended monitoring frequency in most international guidance [1] [2] [3] and with our previous work [11] , although our data more explicitly support the view that two to three times per year is equally as effective as four times per year in achieving commonly used targets in suboptimally controlled diabetes patients. Importantly, our findings appeared important relative to other factors, suggesting that monitoring interval is worthy of further attention in considering opportunities to intervene in order to achieve the recommended target.
Although there were no differences in the rates of transition to optimal control between male and female patients, there was a small increase in the likelihood of achieving optimal control for older patients. This may relate to the observation that HbA 1c values tended to be lower for older patients (−0.27 mmol/mol per year difference in age; Supplementary Figure S2 ). These findings are consistent with findings in a systematic review by Mannucci et al., which showed that older age was associated with a higher success rate for achieving targets in both type 1 and type 2 DM [25] . The CREDIT study demonstrated that younger age was associated with being above the 53 mmol/mol (7.0%) HbA 1c target [26] after correction for a 
Changes of HbA 1c levels over time
The longitudinal analysis on the relationship between tests/year and change in HbA 1c was generally consistent with findings from the dynamic modelling analysis. This showed that one test/year results in, on average, an increase in HbA 1c of 2.64 mmol/mol (0.24%) compared with four tests/year. Extrapolating from UKPDS data [29] , this would equate to a difference in risk of 5% for diabetes-related deaths, 3% for myocardial infarction, 3% for stroke, 4% for heart failure and 9% for microvascular complications.
Strengths and limitations
Although this study indicates the overall optimum testing frequency in order to achieve commonly used targets in a large cohort across three centres using dynamic modelling, we recognise that there are limitations to the study. Laboratory records provide limited access to clinical data, and we were therefore unable to explore other factors such as the differentiation between type 1 and type 2 diabetes (or gestational diabetes), or treatment/lifestyle interventions that may influence the frequency of monitoring and rates of achieving targets. Neither did we explore the reasons lack of monitoring, a topic that has been examined elsewhere [30] [31] [32] [33] and was beyond the scope of this study. We restricted the analysis to patients with suboptimally controlled diabetes, so results cannot be generalised to the whole population of patients with diabetes. We also recognise that guidance suggests agreeing specific treatment targets for individual patients, and so our definition of the cutoff for optimal control (<53 mmol/mol [<7%]) could be perceived as an overgeneralisation. However, our results indicate that testing frequency is important, a finding that is of particular concern following previous work showing that many patients do not have tests at the recommended intervals [4] [5] [6] [7] [8] [9] [10] .
To our knowledge, this study is the first to provide a dynamic assessment of glycaemic control. This was achieved by modelling a patient's rate of transition within a year, from suboptimal to optimal control, as a function of frequency of HbA 1c testing the previous year, patient characteristics and centre. By contrast, previous observational studies are limited in their use of a single post-baseline HbA 1c measurement (or average of a few follow-up measurements) in standard logistic regression analysis to estimate the probability of achieving glycaemic control post-baseline.
As distinct from other studies, we did not stratify by baseline HbA 1c . Such stratification has been attempted in previous observational cross-sectional studies by adjusting for the baseline HbA 1c in linear or logistic regression analysis of a post-baseline HbA 1c measurement (e.g. [21, 34] ). Although it may seem sensible to adjust for the baseline value because this is likely to predict the post-baseline HbA 1c measurement, it has been shown [35, 36] that adjusting for the baseline value in observational studies may introduce bias into the estimates of the effect of an exposure (frequency of testing in the present context).
Conclusions
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